This program project grant is in response to RFA-CA-08-020 entitled "Tumor Stem Cells in Cancer Biology, Prevention, and Therapy". Recent evidence suggests that cancers have a cellular hierarchy in which a minority population of cancer cells, called cancer stem cells, drives the growth and spread of a tumor. The ability to prospectively identify tumorigenic cancer cells will facilitate the identification of pathways that regulate their growth, metastasis and survival in patients. Targeting the pathways involved in essential processes such as self renewal may lead to more effective therapies. This proposal is an interlocking set of projects designed to identify new cancer stem cell therapeutic targets against breast cancer and leukemia stem cells and to test drugs against some of these targets in a preclinical cancer stem cell model. The three projects of our Program are listed below. Project 1: Identification of self-renewal pathways in breast cancer stem cells and development of therapeutic pharmacological interventions. PI Mike Clarke, Stanford University. Project 2: Therapeutic targeting of CD47 on human leukemia and other cancer stem cells PI, Irv Weissman, Stanford University. Project 3: Microfluidic techniques for the molecular and functional analysis of gene expression, chromatin structure and in vitro culturing of cancer stem cells. PI Steve Quake, Stanford University. These projects are highly interconnected and reliant on each other for the success of the individual project as well as the success of this program. Each project will be supported by 4 cores: an administrative core, a bioinformatics core, an animal model core, and a flow cytometry core.
The focus of this application is to identify new therapeutic targets and drugs against breast and leukemia cancer stem cells. Success of this project would lead to more effective cancer therapeutics. This has obvious immense relevance to public health.
|Lee, Cleo Yi-Fang; Lin, Yuan; Bratman, Scott V et al. (2014) Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation. Cancer Res 74:341-52|
|Wang, Jianbin; Quake, Stephen R (2014) RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc Natl Acad Sci U S A 111:13157-62|
|Wu, Angela R; Neff, Norma F; Kalisky, Tomer et al. (2014) Quantitative assessment of single-cell RNA-sequencing methods. Nat Methods 11:41-6|
|Pan, Ying; Volkmer, Jens-Peter; Mach, Kathleen E et al. (2014) Endoscopic molecular imaging of human bladder cancer using a CD47 antibody. Sci Transl Med 6:260ra148|
|Isobe, Taichi; Hisamori, Shigeo; Hogan, Daniel J et al. (2014) miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway. Elife 3:|
|Edris, Badreddin; Willingham, Stephen B; Weiskopf, Kipp et al. (2013) Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth. Proc Natl Acad Sci U S A 110:3501-6|
|Tseng, Diane; Volkmer, Jens-Peter; Willingham, Stephen B et al. (2013) Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A 110:11103-8|
|Pang, Wendy W; Pluvinage, John V; Price, Elizabeth A et al. (2013) Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci U S A 110:3011-6|
|Weiskopf, Kipp; Ring, Aaron M; Ho, Chia Chi M et al. (2013) Engineered SIRP* variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341:88-91|
|Bockhorn, Jessica; Yee, Kathy; Chang, Ya-Fang et al. (2013) MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Res Treat 137:373-82|
Showing the most recent 10 out of 21 publications